A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma
(DURGA-4)
(DURGA-4)
Phase: Phase III clinical trials
Principal Investigator: Prof. Corradini Paolo
Main Facility: Ematologia
Drug: AZD0120
Pathologies: Hematologic malignancies (Lymphomas, Leukemias, Myelomas, and others)
ClinicalTrials.gov: Read the details about clinical trials
BCMA is a surface antigen highly expressed on cells of B-cell lineage and has been shown to be a clinically promising target in MM. CAR T-cell therapy targeting only BCMA is highly efficacious even in advanced MM (ABECMA , Ciltacabtagene autoleucel.
The combined CD19 and BCMA-targeting is anticipated to affect a wider range of malignant plasma cells including MM progenitor cells, which express CD19. The response rates and the manageable AEs observed in the prior and ongoing clinical studies support further investigation of AZD0120 in the current study.
Given that a patient’s immune fitness can be critical for the degree of benefit of CAR-T therapy and depth of response that AZD0120 can achieve, treating patients with MM who have had less prior exposure with other therapies with AZD0120 may provide enhanced clinical benefit.
Altogether, this supports further investigation of AZD0120 in RRMM participants who have received 1 to 3 prior lines of therapy.
Last update: 10/11/2026